Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Original Article

Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study

Seogsong Jeong, Yun Hwan Oh, Joseph C Ahn, Seulggie Choi, Sun Jae Park, Hye Jun Kim, Gyeongsil Lee, Joung Sik Son, Heejoon Jang, Dong Hyeon Lee, Meng Sha, Lei Chen, Won Kim, Sang Min Park

Clin Mol Hepatol. 2024;30(3):487-499. Published online May 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0145

View: 3347 Download: 247 Web of Science: 1 Crossref: 2

Letter to the Editor

Non-alcoholic fatty liver disease and risk of dementia: Unmet need for a pooled analysis of cohort studies

Seogsong Jeong, Won Kim, Sang Min Park

Clin Mol Hepatol. 2022;28(4):933-934. Published online September 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0267

View: 3521 Download: 74

Original Article

Association of non-alcoholic fatty liver disease with incident dementia later in life among elder adults

Seogsong Jeong, Yun Hwan Oh, Seulggie Choi, Jooyoung Chang, Sung Min Kim, Joung Sik Son, Gyeongsil Lee, Joseph C Ahn, Dong Hyeon Lee, Bo Kyung Koo, Won Kim, Sang Min Park

Clin Mol Hepatol. 2022;28(3):510-521. Published online March 17, 2022

DOI: https://doi.org/10.3350/cmh.2021.0332

View: 7556 Download: 320 Web of Science: 33 Crossref: 32

Correspondence

Reply to “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma”

Seogsong Jeong, Won Kim, Sang Min Park

Received December 23, 2024 Accepted January 2, 2025

DOI: https://doi.org/10.3350/cmh.2024.1171 [Accepted]

View: 150 Download: 6

Reply to “MAFLD or MASLD: Which Better Represents the Prognosis of the Steatotic Liver Population”

Seogsong Jeong, Won Kim, Sang Min Park

Received December 26, 2024 Accepted January 2, 2025

DOI: https://doi.org/10.3350/cmh.2024.1175 [Accepted]

View: 209 Download: 8

1 |

Viewed By 6180	MAFLD: How is it different from NAFLD?
Viewed By 5274	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4999	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 4168	Examining the therapeutic landscape of beta-blockers in portal hypertension
Viewed By 3941	Gut microbiome and metabolome signatures in liver cirrhosis-related complications

Cited By 272	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 225	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 155	MAFLD: How is it different from NAFLD?
Cited By 79	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 76	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Search